vimarsana.com
Home
Live Updates
Aficamten Advancing for Cardiomyopathy After SEQUOIA-HCM : vimarsana.com
Aficamten Advancing for Cardiomyopathy After SEQUOIA-HCM
The investigational oral drug leads to "clinically meaningful" improvements in obstructive hypertrophic cardiomyopathy, a pivotal trial shows.
Related Keywords
Lisbon ,
Lisboa ,
Portugal ,
United Kingdom ,
Burlington ,
Massachusetts ,
United States ,
Mayo Clinic In Rochester ,
Minnesota ,
Stever Ommen ,
Perrym Elliott ,
Martins Maron ,
,
Department Of Medicine ,
University Of Glasgow ,
Metabolic Health ,
School Of Cardiovascular ,
Hypertrophic Cardiomyopathy Center At Lahey Hospital ,
Hypertrophic Cardiomyopathy Center ,
Lahey Hospital ,
Medical Center ,
Heart Failure Association ,
European Society ,
New England Journal ,
Cardiovascular Science ,
University College London ,
Mayo Clinic ,
Kansas City Cardiomyopathy Questionnaire ,
Clinical Summary Score ,
vimarsana.com © 2020. All Rights Reserved.